Literature DB >> 6301321

Small-cell carcinoma of lung: reinduction therapy after late relapse.

G Batist, D C Ihde, A Zabell, A S Lichter, S R Veach, M H Cohen, D N Carney, P A Bunn.   

Abstract

Some patients with small-cell carcinoma of lung can be expected to achieve long-term disease-free survival. However, relapses may occur even after 2 years. Information on the treatment of these patients is sparse, although response rates to "salvage" therapy in patients with progressive disease while receiving treatment are poor. We report six patients who had relapses after more than 2 years in complete remission. Five patients were retreated with chemotherapy including some or all of the drugs in the initial treatment, and four had responses with a median duration of 10 months (range, 2 to 18 months). Thus retreatment with chemotherapy similar to the initial treatment can occasionally achieve second responses persisting up to 1 year or longer. The high incidence of patients who have relapses after 2 years confirms previous data on relatively slow growth rates in small-cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6301321     DOI: 10.7326/0003-4819-98-4-472

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  8 in total

1.  Treatment of relapse of small cell lung cancer in selected patients with the initial combination chemotherapy carboplatin, etoposide, and epirubicin.

Authors:  P Collard; P Weynants; C Francis; D O Rodenstein
Journal:  Thorax       Date:  1992-05       Impact factor: 9.139

Review 2.  Rechallenging with anthracyclines and taxanes in metastatic breast cancer.

Authors:  Carlo Palmieri; Jonathan Krell; Colin R James; Catherine Harper-Wynne; Vivek Misra; Susan Cleator; David Miles
Journal:  Nat Rev Clin Oncol       Date:  2010-08-31       Impact factor: 66.675

3.  First-line chemotherapy rechallenge after relapse in small cell lung cancer.

Authors:  M Vincent; B Evans; I Smith
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 4.  Novel strategies for the treatment of small-cell lung carcinoma.

Authors:  William N William; Bonnie S Glisson
Journal:  Nat Rev Clin Oncol       Date:  2011-06-21       Impact factor: 66.675

5.  Topotecan in the treatment of relapsed small cell lung cancer.

Authors:  Elisabeth Quoix
Journal:  Onco Targets Ther       Date:  2008-12-01       Impact factor: 4.147

Review 6.  Intraperitoneal therapy in the management of ovarian carcinoma.

Authors:  M Markman; T Hakes; B Reichman; W Hoskins; S Rubin; W Jones; L Almadones; J L Lewis
Journal:  Yale J Biol Med       Date:  1989 Jul-Aug

Review 7.  Current concepts in the management of small cell lung cancer.

Authors:  Apar Kishor Ganti; William W West; Weining Zhen
Journal:  Indian J Med Res       Date:  2013-06       Impact factor: 2.375

8.  Transcriptomic analysis associated with reversal of cisplatin sensitivity in drug resistant osteosarcoma cells after a drug holiday.

Authors:  Divya Niveditha; Harshita Sharma; Syamantak Majumder; Sudeshna Mukherjee; Rajdeep Chowdhury; Shibasish Chowdhury
Journal:  BMC Cancer       Date:  2019-11-05       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.